Phase II randomised placebo controlled NEOadjuvant chemotherapy study of Nintedanib with Gemcitabine and Cisplatin in locally advanced muscle invasive BLADder cancEr

Trial Profile

Phase II randomised placebo controlled NEOadjuvant chemotherapy study of Nintedanib with Gemcitabine and Cisplatin in locally advanced muscle invasive BLADder cancEr

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Nintedanib (Primary) ; Cisplatin; Gemcitabine
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Acronyms NEOBLADE version: 2
  • Most Recent Events

    • 07 Dec 2015 Accrual to date is 23% according to the United Kingdom Clinical Research Network record.
    • 04 Nov 2015 Accrual to date is 20% according to the United Kingdom Clinical Research Network record.
    • 05 Oct 2015 Accrual to date is 17% according to the United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top